270 related articles for article (PubMed ID: 31558911)
1. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry.
Calapai G; Mannucci C; Chinou I; Cardia L; Calapai F; Sorbara EE; Firenzuoli B; Ricca V; Gensini GF; Firenzuoli F
Evid Based Complement Alternat Med; 2019; 2019():2509129. PubMed ID: 31558911
[TBL] [Abstract][Full Text] [Related]
2. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
3. A scoping review of the use of cannabidiol in psychiatric disorders.
Kirkland AE; Fadus MC; Gruber SA; Gray KM; Wilens TE; Squeglia LM
Psychiatry Res; 2022 Feb; 308():114347. PubMed ID: 34952255
[TBL] [Abstract][Full Text] [Related]
4. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA; Guimarães FS; Campos AC; Zuardi AW
Front Immunol; 2018; 9():2009. PubMed ID: 30298064
[No Abstract] [Full Text] [Related]
5. The therapeutic role of Cannabidiol in mental health: a systematic review.
Khan R; Naveed S; Mian N; Fida A; Raafey MA; Aedma KK
J Cannabis Res; 2020 Jan; 2(1):2. PubMed ID: 33526132
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for cannabidiol in psychiatry?
Khoury JM; Neves MCLD; Roque MAV; Queiroz DAB; Corrêa de Freitas AA; de Fátima Â; Moreira FA; Garcia FD
World J Biol Psychiatry; 2019 Feb; 20(2):101-116. PubMed ID: 28112021
[TBL] [Abstract][Full Text] [Related]
7. Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models.
Domingos LB; Silva NR; Chaves Filho AJM; Sales AJ; Starnawska A; Joca S
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421839
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
Newton M; Newton DW
J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
[No Abstract] [Full Text] [Related]
11. Cannabidiol in Anxiety and Sleep: A Large Case Series.
Shannon S; Lewis N; Lee H; Hughes S
Perm J; 2019; 23():18-041. PubMed ID: 30624194
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.
Elms L; Shannon S; Hughes S; Lewis N
J Altern Complement Med; 2019 Apr; 25(4):392-397. PubMed ID: 30543451
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review.
Dammann I; Rohleder C; Leweke FM
Pharmacopsychiatry; 2024 May; 57(3):115-132. PubMed ID: 38267003
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.
Masataka N
Front Psychol; 2019; 10():2466. PubMed ID: 31787910
[TBL] [Abstract][Full Text] [Related]
17. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
[TBL] [Abstract][Full Text] [Related]
19. Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review.
Matheson J; Bourgault Z; Le Foll B
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291671
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis.
Han K; Wang JY; Wang PY; Peng YC
Psychiatry Res; 2024 Jun; 339():116049. PubMed ID: 38924898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
